Peptide Reference
ARA-290
ARA-290
A synthetic peptide derived from erythropoietin that promotes tissue protection and neuropathic pain relief without stimulating red blood cell production.
Status
clinical
Category
healing
Typical cost
$100-250/vial (10mg)
Mechanism
Activates the innate repair receptor, triggering anti-inflammatory and tissue-protective responses. Promotes nerve regeneration and reduces neuropathic pain without hematopoietic effects.
Potential benefits
- Neuropathic pain relief
- Nerve regeneration
- Tissue protection
- Anti-inflammatory
- No blood cell effects
Reported side effects
- Mild injection site reactions
- Limited long-term data
Common dosing references
subcutaneous
1-4mg · 2-3x weekly
4-8 weeks
Research notes
ARA-290 in diabetic neuropathy
2015
Demonstrated significant pain reduction and nerve fiber regeneration in Phase 2 trials
Regulatory and sourcing notes
Phase II/III clinical trials for neuropathic pain and sarcoidosis. Not FDA-approved yet.
Clinical trial stage. Limited availability. Promising for nerve pain.
Find peptide-aware clinics
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.